PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank67
3Y CAGR+19.1%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+19.1%/yr
vs +131.0%/yr prior
Acceleration
-111.8pp
Decelerating
Percentile
P67
Within normal range
vs 3Y Ago
1.7x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.27% |
| Q3 2025 | -171.15% |
| Q2 2025 | 485.86% |
| Q1 2025 | -107.14% |
| Q4 2024 | -106.28% |
| Q3 2024 | 1638.75% |
| Q2 2024 | 317.26% |
| Q1 2024 | -122.22% |
| Q4 2023 | 187.65% |
| Q3 2023 | -2426.19% |
| Q2 2023 | -609.89% |
| Q1 2023 | 101.71% |
| Q4 2022 | 6.67% |
| Q3 2022 | -8.57% |
| Q2 2022 | -85.77% |
| Q1 2022 | 21.84% |
| Q4 2021 | 4.39% |
| Q3 2021 | -6.77% |
| Q2 2021 | -26.82% |
| Q1 2021 | 20.32% |
| Q4 2020 | -7.47% |
| Q3 2020 | -17.87% |
| Q2 2020 | 14.29% |
| Q1 2020 | 17.99% |
| Q4 2019 | 5.91% |
| Q3 2019 | 0.44% |
| Q2 2019 | -68.49% |
| Q1 2019 | 34.81% |
| Q4 2018 | 14.65% |
| Q3 2018 | 6.18% |
| Q2 2018 | 36.24% |
| Q1 2018 | -11.96% |
| Q4 2017 | -7.46% |
| Q3 2017 | -46.15% |
| Q2 2017 | 9.91% |
| Q1 2017 | -31.49% |
| Q4 2016 | 5.52% |
| Q3 2016 | 8.02% |
| Q2 2016 | 37.36% |
| Q1 2016 | -9.48% |